期刊
JOURNAL OF IMMUNOLOGY
卷 196, 期 6, 页码 2699-2710出版社
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.1502478
关键词
-
类别
资金
- Medical Research Council Senior Non-Clinical Fellowship [G1002046]
- Medical Research Council [G0902266]
- National Institute for Health Research Biomedical Research Centre at Imperial College Healthcare National Health Services Trust
- High-Resolution Electron Cryo-Microscopy Facility at The University of Edinburgh (Wellcome Trust) [WT087658]
- High-Resolution Electron Cryo-Microscopy Facility at The University of Edinburgh (Scottish University Life Science Alliance)
- Medical Research Council [G0902266, G1002046, MR/L008394/1] Funding Source: researchfish
- MRC [G0902266, G1002046, MR/L008394/1] Funding Source: UKRI
Respiratory syncytial virus (RSV) is a leading cause of respiratory tract infection in infants, causing significant morbidity and mortality. No vaccine or specific, effective treatment is currently available. A more complete understanding of the key components of effective host response to RSV and novel preventative and therapeutic interventions are urgently required. Cathelicidins are host defense peptides, expressed in the inflamed lung, with key microbicidal and modulatory roles in innate host defense against infection. In this article, we demonstrate that the human cathelicidin LL-37 mediates an antiviral effect on RSV by inducing direct damage to the viral envelope, disrupting viral particles and decreasing virus binding to, and infection of, human epithelial cells in vitro. In addition, exogenously applied LL-37 is protective against RSV-mediated disease in vivo, in a murine model of pulmonary RSV infection, demonstrating maximal efficacy when applied concomitantly with virus. Furthermore, endogenous murine cathelicidin, induced by infection, has a fundamental role in protection against disease in vivo postinfection with RSV. Finally, higher nasal levels of LL-37 are associated with protection in a healthy human adult RSV infection model. These data lead us to propose that cathelicidins are a key, nonredundant component of host defense against pulmonary infection with RSV, functioning as a first point of contact antiviral shield and having additional later-phase roles in minimizing the severity of disease outcome. Consequently, cathelicidins represent an inducible target for preventative strategies against RSV infection and may inform the design of novel therapeutic analogs for use in established infection.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据